Annukka Pasanen

7PUBLICATIONS
18CO-AUTHORS
Molecular targetsPredictive and prognostic markersMedical molecular engineering of nucleic acids and proteinsMedical mycologyEpigenetics (incl. genome methylation and epigenomics)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Nov 10, 2023
Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer.

D C A Quixabeira, S Pakola, E Jirovec

|Sep 04, 2023
Improving the cytotoxic response of tumor-infiltrating lymphocytes towards advanced stage ovarian cancer with an oncolytic adenovirus expressing a human vIL-2 cytokine.

D C A Quixabeira, E Jirovec, S Pakola

|Sep 02, 2021
Differential impact of clinicopathological risk factors within the 2 largest ProMisE molecular subgroups of endometrial carcinoma.

Annukka Pasanen, Mikko Loukovaara, Terhi Ahvenainen

|Dec 23, 2020
3'RNA Sequencing Accurately Classifies Formalin-Fixed Paraffin-Embedded Uterine Leiomyomas.

Miika Mehine, Sara Khamaiseh, Terhi Ahvenainen

|Feb 16, 2020
Clinicopathological significance of deficient DNA mismatch repair and MLH1 promoter methylation in endometrioid endometrial carcinoma.

Annukka Pasanen, Mikko Loukovaara, Ralf Bützow

|Sep 19, 2018
Genetic predisposition to uterine leiomyoma is determined by loci for genitourinary development and genome stability.

Niko Välimäki, Heli Kuisma, Annukka Pasanen

Pageof 2

Frequent Collaborators

2 joint publications

D C A Quixabeira

2 joint publications

S Pakola

2 joint publications

T V Kudling

2 joint publications

M Anttila